Utility of novel composite index in predicting the prognosis of total neoadjuvant therapy for locally advanced rectal cancer: A multicenter real-world cohort study
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.08.011 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Peng Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, C-Reactive Protein, Serum Albumin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fujian provincial health technology project, Fujian Provincial Hospital, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
OBJECTIVE: C-reactive protein-albumin-lymphocyte (CALLY) is a novel composite index. Total neoadjuvant therapy (TNT) has become one of the standard treatments for locally advanced rectal cancer (LARC). It remains unclear whether CALLY can predict the prognosis for LARC patients. METHODS: Restricted cubic spline (RCS) was employed to assess the relationships of CALLY with perioperative complications, pathologic complete response (pCR), disease-free survival (DFS) and overall survival (OS). RESULTS: This multicenter, real-world study included 995 LARC patients treated with TNT. RCS analysis demonstrated a linear association between CALLY and TNT-related adverse events, postoperative complications, DFS, and OS (all P for nonlinear > 0.05, P overall < 0.05). The high CALLY group (≥13.5) had significantly better DFS and OS than the low CALLY (P < 0.001). The 3- and 5-year DFS of low CALLY patients were 63.0 % and 51.6 %, and the 3- and 5-year OS were 75.6 % and 59.7 %, respectively. In the high CALLY group, the 3- and 5-year DFS were 87.0 % and 77.6 %, and the 3- and 5-year OS were 90.1 % and 81.8 %. CONCLUSION: Baseline CALLY can serve as an effective prognostic tool for LARC patients undergoing TNT and guide personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, China.
- Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, China; Shengli Clinical…
- Surgical Anesthesiology Department, Zhongshan Hospital Xiamen University.
- Department of Hepatobiliary Pancreatic Surgery, The First Hospital of PuTian City, Putian, Fujian 351100, China.
- Anorectal Surgical Department, Hangzhou Red Cross Hospital, Hangzhou, Zhenjiang, China.
- Department of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350004, China.
Förderung
- Fujian provincial health technology project
- Fujian Provincial Hospital
- Natural Science Foundation of Fujian Province
Zitieren
APA
Ye, P., Chen, Y., Ye, F., Chen, W., Zhou, Z., Ye, R., Jia, H., Zheng, T., & Zheng, C. (2025). Utility of novel composite index in predicting the prognosis of total neoadjuvant therapy for locally advanced rectal cancer: A multicenter real-world cohort study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.08.011
Vancouver
Ye P, Chen Y, Ye F, Chen W, Zhou Z, Ye R, et al. Utility of novel composite index in predicting the prognosis of total neoadjuvant therapy for locally advanced rectal cancer: A multicenter real-world cohort study. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.08.011
BibTeX
@article{Ye2025,
author = {Ye, Peng and Chen, Yizhen and Ye, Fang and Chen, Weijie and Zhou, Zhenyuan and Ye, Rong and Jia, Hangdong and Zheng, Ting and Zheng, Chunying},
title = {Utility of novel composite index in predicting the prognosis of total neoadjuvant therapy for locally advanced rectal cancer: A multicenter real-world cohort study},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.08.011}
}
EUVIMED